The method detection limits for remaining compounds were limited by field and laboratory blanks.
However, the ability to produce these economically important compounds is limited, because it is both expensive and technically challenging to separate omega-3 polyunsaturated fatty acids (ω-3 PUFAs) from natural oils.
However, identification of odorants and compounds is limited by several factors, including both the availability of chemicals and the need to present chemicals individually and in combination to detection canines.
For this reason, the number of inorganic compounds is limited in spite of the large number of elements that may react with each other.
The overall chemical space covered by synthetic compounds is limited as compared to natural compounds given their higher chemical diversity [9].
However, the therapeutic use of most of these compounds is limited since they do not cross the blood brain barrier (BBB).
While these approaches have been successfully used in test cases, their utility in finding novel active compounds is limited due to fact that the new compounds selected are often structurally similar to the compounds that are initially used as templates.
The choice of macromolecular compounds is limited by the fact that high luminescent stable ZnO nanocrystals has been obtained in a limited range of solvents such as ethanol, isopropanol, and dimethylformamide [11].
Although the thermochemical and thermophysical properties of minor actinide compounds are essential for the design of MA-bearing fuels and analysis of their behavior, the experimental data on minor actinide compounds are limited.
However, in spite of seemingly adequate exposure achieved upon IV administration, the in vivo efficacy of the early lead compounds was limited by high levels of binding to serum proteins.
